"MODELLING THE U.S. POPULATION HEALTH BENEFITS OF FURTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION WITH ALIROCUMAB AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL" by Robert Sanchez

Selected Works of Robert Sanchez, MD, FACC

Article

MODELLING THE U.S. POPULATION HEALTH BENEFITS OF FURTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION WITH ALIROCUMAB AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL

Journal of the American College of Cardiology (2017)

Robert Sanchez, Regeneron
Robert Sanchez, Sanofi S.A.
Khurram Nasir, Regeneron
Khurram Nasir, Sanofi S.A.
Alexa Klimchak, Regeneron
Alexa Klimchak, Sanofi S.A.
Andreas Kuznik, Regeneron
Andreas Kuznik, Sanofi S.A.
Florence Joulain, Regeneron
Florence Joulain, Sanofi S.A.
Andrew Briggs, Regeneron
Andrew Briggs, Sanofi S.A.

Link

Disciplines

Publication Date

March 21, 2017

DOI

10.1016/S0735-1097(17)33455-1

Citation Information

Robert Sanchez, Robert Sanchez, Khurram Nasir, Khurram Nasir, et al.. "MODELLING THE U.S. POPULATION HEALTH BENEFITS OF FURTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION WITH ALIROCUMAB AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL" Journal of the American College of Cardiology Vol. 69 Iss. 11 (2017) p. 66
Available at: http://works.bepress.com/robert-sanchez/18/